Genome Engineering Market, By Technology (CRISPR, TALEN, ZFN, and others), By Application (Cell Line Engineering, and Genetic Engineering), By End User (Biotechnology & Pharmaceutical Companies, Research Institutes, and Contract Research Organizations) and by Geography - Global Trends and Forecast to 2025

  • Published On : Apr 2018 |
  • Pages : 185 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Genome Engineering Market- Insights

Genome engineering is a process of insertion, deletion, modification or replacement of DNA bases in an organism. There are two types of gene therapy, Ex-Vivo Gene Therapy and In-Vivo Gene Therapy. Ex-vivo gene therapy involves the transfer of genes in cultured cells and then reintroducing in patient, while in In-vivo gene therapy, genes are directly delivered in cells of a particular tissue. Key companies such as CRISPR Therapeutics AG, Editas Medicine, Inc., and Intellia Therapeutics, Inc. are focusing on developing In-Vivo and Ex-vivo gene therapy. Major techniques used in genome engineering are CRISPR, TALEN, and ZFN. CRISPR (CRISPR-Cas9). These are innovative genome editing tools that enable researchers to edit parts of the genome by adding, removing, or altering sections of the DNA sequence. CRISPR is an accurate, faster, and cheaper technique for editing DNA as compared to others methods such as TALEN and ZFN. Transcription activator-like effector nucleases (TALEN) is a technology widely used in live cell gene editing. Zinc-finger nucleases (ZFNs) is an artificial restriction enzyme, which simplifies targeted editing of genome by creating double-strand breaks in DNA at user-specified locations.

Increasing development of novel technologies in genome engineering is expected to drive growth of the global genome engineering market in the near future

Key players in the market are focusing on developing novel technologies and launching new products for genome engineering, in order to increase their market share. For instance, in February 2018, Sangamo Therapeutics, Inc. received clinical trial authorization (CTA) from Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. for its SB-FIX, a zinc finger nuclease (ZFN)-mediated in-vivo genome editing treatment for hemophilia B. CTA has allowed for the beginning of Europe's first in-vivo genome editing study. In 2017, Integrated DNA Technologies, Inc. launched the first Cas9 enzyme variant, which reduces off-target effects in CRISPR genome editing. The launch of latest Cas9 enzyme variant is a major step towards therapeutic use of CRISPR. In 2017, Scientists at Salk Institute for Biological Studies, modified CRISPR to epigenetically treat diabetes, kidney disease, and muscular dystrophy. They developed a latest version of CRISPR/Cas9 genome editing technology, which allows for activation of genes without creating breaks in the DNA. The development of such novel technologies is expected to be major driving factor for growth of global genome engineering market.

The global genome engineering market was valued at US$ 2,582.7 Mn in 2016 and is expected to witness a CAGR of 14.3% over the forecast period (2017–2025).

Figure 1. Global Genome Engineering Market Share (%), By Technology, 2017–2025

Genome Engineering Market

Source: Coherent Market Insights Analysis (2017)

Increasing strategic collaboration for genome engineering technologies by key players is expected to drive market growth in the near future

Players in the market are focusing on strategic collaborations, in order to increase their product offerings. For instance, in February 2018, Kite Pharma, Inc.—a Gilead Sciences, Inc. company— collaborated with Sangamo Therapeutics Inc. for developing engineered cell therapies to treat cancer. As per the agreement, Kite Pharma, Inc. will use Sangamo Therapeutics’ zinc finger nuclease (ZFN) gene-editing technology for developing next-generation ex vivo cell therapies for treatment of cancer. Furthermore, in 2017, Synthego and Thermo Fisher Scientific collaborated to manufacture and distribute synthetic guide RNA products for CRISPR genome engineering. In 2016, CRISPR Therapeutics and Bayer AG collaborated and formed a joint venture Casebia Therapeutics, for developing CRISPR-based therapeutics in select disease areas. Moreover, in 2017, Casebia Therapeutics collaborated with CureVac AG. According to collaboration agreement, CureVac will develop novel Cas9 mRNA constructs with improved properties for gene editing applications. In 2015, AstraZeneca plc. announced research collaborations with The Wellcome Trust Sanger Institute, The Innovative Genomics Initiative, Thermo Fisher Scientific, and Broad Institute/Whitehead Institute to use their CRISPR technology for genome editing. Such strategic collaborations among major key players and research institutes is expected to drive market growth in the near future.

Moreover, increasing funding and investments for the development and research of new genetic engineering technologies is also expected to drive market growth. For instance, in January 2018, the U.S. National Institutes of Health (NIH) announced to grant US$ 190 million for genome editing research. This new program, Somatic Cell Genome Editing, will award funds to biomedical researchers over the following six years. The support from major research organizations such as NIH is expected to attract more researchers in this field, which may lead to advancements in technology and also aid in growth of the market. 

High cost of genome engineering technologies is expected to be the major factor, restraining growth of the genome engineering market over the forecast period. For instance, according to the fees chart provided by Yale Genome Editing Center, in 2018, it charges between US$ 8,000 and US$ 15,000 for gene editing facilities. The high cost associated with genome engineering facilities is expected to hamper the market growth, especially in emerging economies such as India, Brazil, and South Africa. Moreover, genome engineering is a very complex technology and needs high skilled researchers, which limits its adoption rate.

Key players operating in the genome engineering market include Thermo Fisher Scientific Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Editas Medicine, Inc., Sangamo Therapeutics, Inc., Bluebird Bio, Inc., Cellectis S.A., and Merck Group.

Genome engineering is a technique in which a DNA is inserted, deleted, modified or replaced in the genome of a living organism. Research and development activities are conducted in genome engineering for the development of novel technologies. For instance, in 2017, Synthego Corporation launched a CRISPR Pioneers Program to expand genome engineering research. Researchers are majorly focusing on developing treatments for cancer and rare diseases with the help of genome engineering tools such as CRISPER. Many genome technologies are under trial for treatment of such diseases, and are expected to receive approvals in the near future.

Market Dynamics

Development of novel technologies in genome engineering field is expected to significantly drive growth of the global genome engineering market in the near future. For instance, in 2017, Merck KGaA— Germany-based company—developed a new genome editing tool dubbed 'proxy-CRISPR', providing access to previously inaccessible microenvironments of the genome by modification of chromatin modifications. In 2017, Benson Hill Biosystems, Inc.—an agricultural technology company—launched its latest CRISPR 3.0, to increase innovators’ access to gene editing. CRISPR 3.0 is a latest innovative genomics tool, which is expected to improve crop performance. Development of such novel technologies by major key players is expected to create a conducive environment for growth of market.

Furthermore, increasing strategic collaborations by major key players for genome engineering technologies is also expected to drive market growth. For instance in 2015, ToolGen, Inc.—a South Korea-based company—collaborated with Thermo Fisher Scientific and licensed its CRISPR/Cas9 intellectual property portfolio to Thermo Fisher Scientific. This license agreement has strengthened the relationship between ToolGen and Thermo Fisher in the area of genome editing. In 2014, Cellectis Bioresearch and Thermo Fisher Scientific entered into a strategic collaboration agreement covering the uses of TAL nucleases under the brand name TALEN. As per the agreement, Thermo Fisher Scientific is granted a worldwide license under Cellectis’ rights to the TAL nucleases outside the therapeutic field. Thermo Fisher will market TALEN for these applications under its Life Technologies brand. In 2014, Bluebird Bio, Inc. acquired Precision Genome Engineering (Pregenen) at US$ 139.9 Mn. This acquisition has helped the company to use Pregenen’s MegaTALs, originally developed by Precision Genome Engineering. In 2014, Biogen Idec and Sangamo BioSciences, Inc. entered into a collaboration agreement for the development of treatment of Hemoglobinopathies. According to the collaboration, Biogen Idec will use Sangamo's proprietary zinc finger nuclease (ZFN) genome-editing technology.

Key features of the study:

  • This report provides in-depth analysis of genome engineering market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017–2025), considering 2016 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global genome engineering market  based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
  • Key companies covered as a part of this study include Thermo Fisher Scientific Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Editas Medicine, Inc., Sangamo Therapeutics, Inc., Bluebird Bio, Inc., Cellectis S.A., and Merck Group.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global genome engineering market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the genome engineering market

Detailed Segmentation:

  • Global Genome Engineering Market, By Technology :
    • CRISPR
    • TALEN
    • ZFN
    • Others
  • Global Genome Engineering Market, By Application:
    • Cell Line Engineering
    • Genetic Engineering
  • Global Genome Engineering Market, By End User:
    • Biotechnology & Pharmaceutical Companies
    • Research Institutes
    • Contract Research Organization
  • Global Genome Engineering Market, By Geography:
    • North America
      • By Technology :
        • CRISPR
        • TALEN
        • ZFN
        • Others
      • By Application:
        • Cell Line Engineering
        • Genetic Engineering
      • By End User:
        • Biotechnology & Pharmaceutical Companies
        • Research Institutes
        • Contract Research Organization
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Technology :
        • CRISPR
        • TALEN
        • ZFN
        • Others
      • By Application:
        • Cell Line Engineering
        • Genetic Engineering
      • By End User:
        • Biotechnology & Pharmaceutical Companies
        • Research Institutes
        • Contract Research Organization
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Technology :
        • CRISPR
        • TALEN
        • ZFN
        • Others
      • By Application:
        • Cell Line Engineering
        • Genetic Engineering
      • By End User:
        • Biotechnology & Pharmaceutical Companies
        • Research Institutes
        • Contract Research Organization
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Technology :
        • CRISPR
        • TALEN
        • ZFN
        • Others
      • By Application:
        • Cell Line Engineering
        • Genetic Engineering
      • By End User:
        • Biotechnology & Pharmaceutical Companies
        • Research Institutes
        • Contract Research Organization
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • By Technology :
        • CRISPR
        • TALEN
        • ZFN
        • Others
      • By Application:
        • Cell Line Engineering
        • Genetic Engineering
      • By End User:
        • Biotechnology & Pharmaceutical Companies
        • Research Institutes
        • Contract Research Organization
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Technology :
        • CRISPR
        • TALEN
        • ZFN
        • Others
      • By Application:
        • Cell Line Engineering
        • Genetic Engineering
      • By End User:
        • Biotechnology & Pharmaceutical Companies
        • Research Institutes
        • Contract Research Organization
      • By Country:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Thermo Fisher Scientific Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • CRISPR Therapeutics AG
    • Intellia Therapeutics, Inc.
    • Editas Medicine, Inc.
    • Sangamo Therapeutics, Inc.
    • Bluebird Bio, Inc.
    • Cellectis S.A.
    • Merck Group

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Technology
      • Market Snippet, By Application
      • Market Snippet, By End User
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • PEST Analysis
    • Key Developments
    • Collaboration-Acquisition
    • Porter’s Five Forces Analysis
  4. Global Genome Engineering Market, By Technology, 2015–2025 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2016–2025
      • Segment Trends
    • CRISPR
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
    • TALEN
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
    • ZFN
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
  5. Global Genome Engineering Market, By Application, 2015–2025 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2016–2025
      • Segment Trends
    • Cell Line Engineering
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
    • Genetic Engineering
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
  6. Global Genome Engineering Market, By End User, 2015–2025 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2016–2025
      • Segment Trends
    • Biotechnology & Pharmaceutical Companies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
    • Research Institutes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
    • Contract Research Organization
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
  7. Global Genome Engineering Market, By Region, 2015–2025 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, For Regions, 2016–2025
    • North America
      • Market Size and Forecast, By Technology, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Application, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By End User, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Technology, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Application, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By End User, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Technology, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Application, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By End User, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of APAC
    • Latin America
      • Market Size and Forecast, By Technology, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Application, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By End User, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Technology, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Application, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By End User, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
        • Central Africa
        • South Africa
        • North Africa
    • Middle East
      • Market Size and Forecast, By Technology, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Application, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Thermo Fisher Scientific Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • CRISPR Therapeutics AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Intellia Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Editas Medicine, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sangamo Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Bluebird Bio, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Cellectis S.A.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Merck Group
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 47 market data tables and 42 figures on “Genome Engineering Market - Global forecast to 2025”.

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.